Gail Farfel
Director/Miembro de la Junta en DURECT CORPORATION .
Fortuna: 116 784 $ al 30/04/2024
Cargos activos de Gail Farfel
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| DURECT CORPORATION | Director/Miembro de la Junta | 25/04/2019 | - |
| Independent Dir/Board Member | 25/04/2019 | - | |
| AVROBIO, INC. | Director/Miembro de la Junta | 21/10/2020 | - |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Director/Miembro de la Junta | - | - |
| American Society For Experimental Neurotherapeutics | Director/Miembro de la Junta | - | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Director/Miembro de la Junta | 07/08/2014 | - |
Historial de carrera de Gail Farfel
Antiguos cargos conocidos de Gail Farfel.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Director/Miembro de la Junta | 29/06/2023 | 30/12/2023 |
| Director Ejecutivo | 19/09/2022 | 30/12/2023 | |
| Presidente | 19/09/2022 | 30/12/2023 | |
| ZOGENIX, INC. | Corporate Officer/Principal | 01/06/2015 | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/12/2012 | 01/06/2015 |
| Consejero General | 01/12/2012 | 01/06/2015 | |
| G Meredith Consulting LLC | Presidente | 01/05/2008 | 01/12/2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formación de Gail Farfel.
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 13 |
| Canadá | 3 |
| Reino Unido | 2 |
Operativa
| Director/Board Member | 7 |
| Corporate Officer/Principal | 4 |
| President | 2 |
Sectorial
| Health Technology | 11 |
| Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Empresas privadas | 8 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
| American Society For Experimental Neurotherapeutics |
- Bolsa de valores
- Insiders
- Gail Farfel
- Experiencia
